Kailera Therapeutics, a phase 3 biotech developing injectable and oral GLP-1 agonists for obesity, raised $625 million by offering 39.1 million shares at $16, the high end of the $14 to $16 range. The company originally planned to offer 33.3 million shares at the same range. Existing shareholders Bain Capital and QIA ahd indicated on $225mm of the deal. At pricing, the company commands a fully diluted market value of $2.1 billion (+12% vs. original midpoint).
Kailera is progressing four clinical-stage candidates targeting obesity, leveraging multiple glucagon-like peptide-1 (GLP-1) based mechanisms of action and routes of administration. Its lead candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide receptor dual agonist peptide. The company is expanding its ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide.
The Waltham, MA-based company will trade on the Nasdaq under the symbol KLRA. J.P. Morgan, Jefferies, Leerink Partners, TD Securities, and Evercore ISI acted as joint bookrunners on the deal.
Obesity biotech Kailera Therapeutics prices upsized IPO at $16 high end
April 17, 2026

